# Tepezza hearing loss litigation

> Educational mass tort overview from DrugsMonitor.com. Not legal or medical advice.

**Canonical URL:** https://drugsmonitor.com/case/tepezza-hearing-loss-lawsuit
**Last updated:** 2026-06-11

## Key facts

- **Matter:** Tepezza Hearing Loss
- **Status:** Discovery Phase
- **Scope:** United States — national overview
- **Drug safety page:** https://drugsmonitor.com/drug-info/tepezza-hearing-loss-lawsuit

## Overview

Tepezza (teprotumumab) treats thyroid eye disease. Some patients report permanent hearing loss or tinnitus following infusions, spawning product-liability litigation that examines labeling, pharmacovigilance, and otologic monitoring.

### Clinical use and alleged injuries

Tepezza blocks IGF-1R signaling to reduce proptosis and inflammation in thyroid eye disease. Post-marketing reports and litigation claim defendants understated auditory risks, including sensorineural hearing loss requiring hearing aids or cochlear evaluation.

Causation debates include whether hearing changes stem from the drug, concurrent autoimmune disease, or other ototoxic exposures.

### Litigation status

Cases are centralized in the Northern District of Illinois. Early-phase MDL work focuses on general causation experts, label history, and FDA communications.

As discovery matures, bellwether selections may clarify how juries weigh warning adequacy.

---

*DrugsMonitor.com is not a law firm. For medical decisions consult a licensed clinician; for legal decisions consult a qualified attorney.*